{"entity":{"id":"nct03873402","kind":"trial","name":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","aka":[],"tldr":"A phase 3 trial of Nivolumab, Ipilimumab in renal cell carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer is a phase 3 interventional study registered as NCT03873402 by Bristol-Myers Squibb, with 437 participants enrolled, started 2019-06-21 and due to reach its primary completion in 2027-03-11. Interventions recorded: Nivolumab, Ipilimumab, Ipilimumab placebo. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03873402","url":"https://clinicaltrials.gov/study/NCT03873402"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03873402","phase":"3","setting":"A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT03873402","source":"https://clinicaltrials.gov/study/NCT03873402","fetchedAt":"2026-10-07T16:53:10.205Z","studySha256":"6ac1a2b490b2cca01a56f57872b89b38520837ee947bff97b3551fe3f35b52a7","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-01-21","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":437,"enrolmentType":"ACTUAL","siteCount":78,"recruitingSiteCount":0,"countries":["Argentina","Austria","Chile","Czechia","France","Greece","Italy","Mexico","Poland","Portugal","Romania","Russia","Spain","United States"]}],"started":"2019-06-21","startedType":"actual","enrolled":437,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03873402/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}